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Vasoactive intestinal peptide (VIP) plays diverse and important role in human physiology
and physiopathology and their receptors constitute potential targets for the treatment of
several diseases such as neurodegenerative disorder, asthma, diabetes, and inﬂammatory
diseases. This article reviews the current knowledge regarding the two VIP receptors,
VPAC1 and VPAC2, with respect to mechanisms involved in receptor activation, G protein
coupling, signaling, regulation, and oligomerization.
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VASOACTIVE INTESTINAL PEPTIDE
Vasoactive intestinal peptide (VIP) is a 28 amino acids peptide
isolated from porcine intestine (Said and Mutt, 1970) and that
belongs to a family of structurally related peptide hormones that
includes secretin, pituitary adenylate cyclase-activating polypep-
tide (PACAP), glucagon, glucagon-like peptides (GLP), gastric
inhibitory peptide (GIP), and growth hormone-releasing hor-
mone (GHRH). It has initially been shown that VIP has a diverse
range of effects such as vasodilation, relaxation of smooth muscle
in intestinal and pulmonary tissues, and stimulation of electrolyte
secretion in the gut (Dickson and Finlayson, 2009; Harmar et al.,
2012). As a consequence,VIP was ﬁrst classiﬁed as a gut hormone.
Later studies demonstrated that VIP has a more expanded dis-
tribution including peripheral (PNS) and central (CNS) nervous
system (Larsson et al., 1976a,b) as well as cells and tissues of the
immune system (Delgado et al., 2004), suggesting that VIP may
also behave as a neuroendocrine hormone, a neurotransmitter
and a cytokine-like peptide. Many studies supported this hypoth-
esis and it is now well accepted that VIP plays important role in
the CNS such as control of circadian rhythms, anxiety, response
to stress, schizophrenia, learning, and memory (King et al., 2003;
Dickson and Finlayson, 2009; Moody et al., 2011; Harmar et al.,
2012). In the periphery, it is involved in the control of insulin
secretion from thepancreas and the release of catecholamines from
the adrenal medulla (Dickson and Finlayson, 2009; Moody et al.,
2011; Harmar et al., 2012). VIP also acts as a co-transmitter of
non-adrenergic non-cholinergic relaxation of vascular and non-
vascular smooth muscles (Said and Rattan, 2004). Finally, in the
immune system VIP has potent effects on T cell differentiation
and migration and modulates cytokine production by T helper
cells (Delgado et al., 2004).
VPAC RECEPTORS
The biological effects of VIP are mediated by two receptors named
VPAC1 and VPAC2 that belong to the family B of G protein-
coupled receptors (GPCRs) which also includes PAC1-, secretin-,
glucagon-,GLP 1 and 2-, calcitonin-,GIP-, corticotropin-releasing
factor (CRF) 1 and2-, andparathyroidhormone receptors. Besides
VIP, VPAC1 and VPAC2 receptors also bind with the same high
afﬁnity PACAP. The VPAC1 receptor was initially cloned from
rat lung (Sreedharan et al., 1993) and the VPAC2 receptor from
rat pituitary (Lutz et al., 1993). Like VIP, VPAC receptors are
widely distributed throughout the body. In theCNS,VPAC1 recep-
tors are abundantly localized in piriform cortex, cerebral cortex,
suprachiasmatic nucleus, hippocampus, and pineal gland (Usdin
et al., 1994) while VPAC2 receptors are mainly found in cerebral
cortex, suprachiasmatic nucleus, thalamus, hypothalamus, and
amygdala (Sheward et al., 1995). Although both receptors may
be co-expressed in the same areas of the CNS, studies suggest
that the two receptor subtypes have complementary distribu-
tion. In peripheral tissues, VPAC1 receptors have been found
in breast, kidney, liver, lung, prostate, spleen, and mucosa of
the gastrointestinal tract (Reubi, 2000). Similarly, VPAC2 recep-
tors have a large distribution and have been localized in adrenal
medulla, blood vessels, lung, pancreatic acinar cells, smooth
muscle, and thyroid follicular cells (Harmar et al., 2004). In the
immune system, VPAC1 receptors are constitutively expressed in
T cells, monocytes, and macrophages while expression of VPAC2
receptors is induced upon activation of T cells and macrophages
(Delgado et al., 2004).
Like all members of the GPCR-B family, VPAC receptors are
heptahelicalmembrane proteins and are characterized by the pres-
ence of a largeN-terminal extracellular domain. The recent solving
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of the NMR or X-ray structure of the N-terminus of several family
B receptors [CRF, PTH, PAC1, GIP, GLP-1, CLR/RAMP1, and
VPAC2(PDB ID: 2X57)] clariﬁed their role in ligand binding. The
structure comprises a crucial sushi domain characterized by two
antiparallel β sheets and stabilized by three disulﬁde bonds and
a salt bridge sandwiched between aromatic rings of two trypto-
phan residues (Harmar et al., 2012). The data support the two-site
model for peptide binding to family B GPCR, in which the N-
terminal domain of the receptor is the principal binding site
for the central and the C-terminal regions of the natural lig-
and and ensures correct ligand positioning, whereas binding of
residues 1–6 of the ligand to the extracellular loops and trans-
membrane helices drives the receptor activation (Hoare, 2005).
More recently, it has also been proposed that a helix N-capping
motif, identiﬁed in the N-terminus of all GPCR-B family lig-
ands and stabilizing their helical conformation, was probably
formed upon receptor binding and could also constitute a key
element in receptor activation (Neumann et al., 2008). Although
the experimental structure of the VPAC1 has not been solved, a
three-dimensional model obtained by homology modeling asso-
ciated with photoafﬁnity experiments supports that VPAC1 shares
the same features (Couvineau and Laburthe, 2012).
SIGNALING PATHWAYS ACTIVATED BY VPAC RECEPTORS
Like all GPCRs, upon agonist binding VPAC receptors undergo
physical/conformational changes that allow interaction of cyto-
plasmic domains with heterotrimeric G proteins and promote
exchange of GDP for GTP on the Gα subunit. This initiates
the dissociation of GTP-bound Gα subunit from Gβγ dimer and
activation of downstream effector pathways. Signals are termi-
nated following hydrolysis of Gα-bound GTP and reformation
of inactive trimeric complex (Pierce et al., 2002). VPAC receptors
are preferentially coupled to Gαs leading to activation of adeny-
late cyclase and subsequent cAMP production. Accumulation of
intracellular cAMP also leads to activation of protein kinase A
(PKA) that may activate the ERK signaling pathway to promote
proliferation (Pechon-Vallee et al., 2000) and neuroendocrine cell
differentiation (Gutierrez-Canas et al., 2005) as seen in pituitary
cells and prostate cancer cell line, respectively. VIP-induced PKA
activation is also responsible for most of the anti-inﬂammatory
activity of VIP by regulating several signaling pathways and tran-
scription factors thus increasing anti-inﬂammatory cytokines and
reducing pro-inﬂammatory cytokines production (Gonzalez-Rey
et al., 2007). Several studies also reported that VPAC receptors
were able to activate phospholipase C (PLC) pathway and stimu-
late calcium levels, either in cells endogenously expressing VPAC
receptors or in transfected cell lines. However, the precise mech-
anisms which contribute to VIP-induced [Ca2+]i increase remain
unclear due to divergent results. Indeed, in transfected cell lines
some studies observed that activation of PLC was partly sensi-
tive to pertussis toxin (PTx; MacKenzie et al., 1996; Langer et al.,
2002), thus involving both Gαi and Gαq coupling, while others
did not observe coupling to Gαi (Sreedharan et al., 1994). More-
over, PTx sensitive mechanisms leading to PLC activation seems
different for VPAC1 and VPAC2 receptors. Cross-linking studies
demonstrated that physical interaction between VPAC1 and Gαi
andVPAC1-induced [Ca2+]i increase are not affected by chelating
of extracellular calcium (Langer et al., 2002), while PTx sensi-
tive activation of PLC by VPAC2 relies on the availability of free
Gβγ and on Ca2+ entry through receptor-operated Ca2+ chan-
nels (MacKenzie et al., 2001). Finally, it was also observed that
both VPAC1 and VPAC2 are able to couple to Gα16, a G protein
of the Gαq family, that enables the coupling of a wide variety of
receptors to PLC and whose expression is restricted to hematopoi-
etic cells (with the exception of the mature B cells; Langer et al.,
2001). These ﬁndings indicate that the speciﬁc G protein/second
messenger complement of the cell line/type being examined could
alter the transduction pathways/pharmacology observed forVPAC
receptors (Figure 1).
Additional coupling events that are not G protein-mediated
may also elicit auxiliary signals. Both VPAC1 and VPAC2 are able
to activate phospholipase D (PLD). PLD responses induced by
VPAC2 are not affected by PLC inhibitors, PTx or PKA inhibitors
but are sensitive to brefeldin A an inhibitor of ADP-ribosylation
factor (ARF) known to act as a direct activator of PLD (McCulloch
et al., 2000). In pancreatic β cells, VIP induced sustained stimu-
lation of insulin secretion is mediated by phosphatidylinositol 3
kinase activation by VPAC2 receptors (Dickinson et al., 1999). In
the rat pineal gland,VIP stimulates cGMP formation through acti-
vation of nitric oxide synthase, NO production and activation of
cytosolic guanylate cyclase (Spessert, 1993).
MOLECULAR MECHANISMS INVOLVED IN VPAC
RECEPTORS ACTIVATION
The recent solving of the X-ray crystal structures of several GPCR-
A family members in complex with agonist, antagonist, and G
proteins provides clues to the transmembrane helix (TM) rear-
rangements that result from agonist binding and subsequent
receptor activation. These include the disruption of an ionic
interaction involving the E/DRY motif located at the cytoplas-
mic face of TM3 and maintaining the receptor preferentially in a
ground inactive conformation in absence of agonist (ionic lock),
a “rotamer toggle switch” (modulation of the helix conforma-
tion around a proline kink) in TM6 causing key sequences to
be exposed to cytoplasmic binding partners and a conformational
change of Y residue of the NPXXY motif located in TM7 sta-
bilizing the active conformation (Rosenbaum et al., 2009, 2011;
Rasmussen et al., 2011). Surprisingly, the predicted interaction
between E/DRY motif located in TM3 and a glutamate residue
located in TM6 (“ionic lock”) was solely observed in rhodopsin
inactive state crystals but not in other GPCR crystals available
to date. Instead, as seen for the β2-adrenergic receptor (β2-AR),
Arg of the E/DRY motif interacts primarily with the adjacent Asp
residue in crystals of β2-AR stabilized with the inverse agonist
carazolol (inactive conformation; Rasmussen et al., 2007; Rosen-
baum et al., 2007) while in crystals of β2-AR/Gs protein complex
(active conformation) this interaction is broken and Arg of the
E/DRY motif packs against a Tyr residue of Gs (Rasmussen et al.,
2011). In absence of X-ray crystal structure of theVPAC receptors,
only model structures of VPAC1 have been reported which used as
template the structures of the N-terminal domain of the CRF 2β
receptor (Ceraudo et al., 2012) or structures of familyAGPCRs for
the transmembrane domains (Conner et al., 2005; Chugunov et al.,
2010). However, the low sequence identity between the sequence
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FIGURE 1 | G protein-dependent signaling pathways activated by
VPAC receptors. VPAC receptors are preferentially coupled to Gαs leading
to activation of adenylate cyclase (AC) and subsequent cAMP production
and activation of protein kinase A (PKA). VPAC receptors are able to activate
phospholipase C (PLC) pathway after coupling to Gαi, Gαq, or Gα16 and
stimulate calcium levels and protein kinase C (PKC). Gαi-dependent
activation of PLC by VPAC2 relies on the availability of free Gβγ and on Ca2+
entry through receptor-operated Ca2+ channels while Gαi-dependent
activation of PLC by VPAC1 is not affected by chelating of extracellular
calcium.
of theVPAC receptors and the templates used for homology mod-
eling prevents direct transposition of molecular switches that drive
GPCR-A members activation.
As all members of GPCR-B family, VPAC receptors lack the
E/DRY sequence. On the basis of subtle changes observed when
Y239 and L240, located in TM3 of VPAC1, were substituted with
alanine it was proposed that this YL sequence was equivalent to
the E/DRY motif of GPCR-A family (Tams et al., 2001). Another
model basedon a three-dimensional analysis of theGLP-1 receptor
proposed that a E/DRY motif could be formed by three non-
adjacent residues consisting inR174 in the cytoplasmic endof TM2,
E236, and Y239 in the distal part of TM3 of VPAC1 (Frimurer and
Bywater, 1999). However, another study showed thatY239A, L240A,
E236A,Y239A, and R174Amutants were undistinguishable from the
wild type receptor (Nachtergael et al., 2006). One possible expla-
nation for the discrepancy can be the fact that Tams et al. (2001)
studied cyclic AMP measurements in intact cells a more sensitive
model than the adenylate cyclase assay on membrane used in the
other study. Nevertheless, even if the YL motif of GPCR-B family
and E/DRY motif of GPCR-A family have the same location, they
certainly do not have the same importance for receptor activation
(Figure 2).
Asmentioned before structural data conﬁrmed thatGPCR acti-
vation is accompanied by modiﬁcation of helix conformation.
For the β2-AR, the largest difference between the inactive and
active structures is a large outward movement of TM6 and an
inward movement of TM7 such as Tyr of the conserved NPxxY
sequence (located in TM7)moves into the space occupied by TM6
in the inactive state. In GPCR-A family conserved prolines located
in TM6 and laying near the ligand binding pocket and in TM7
(NPxxY sequence) play crucial role in these rearrangements due
to their cyclic pyrrolidine ring side chain that introduce kink into
the α-helical structure of TM and allow TM ﬂexibility important
for G protein coupling and signaling. In this line, a study of Knud-
sen et al. (2001) investigated the role of prolines located in TM
of VPAC1 (Figure 2). They found that mutation of P266 (TM4),
P300 (TM5), and P348 (TM6) into alanine signiﬁcantly decrease
VPAC1 expression levels but preserve VIP binding. P266A showed
decreased ability to stimulate cAMP, while P300A and P348A dis-
played an increased potency in cAMP production combined with
a high sensitivity toward GTP compared to the wild type receptor,
thus demonstrating that these prolines are important for overall
structure of VPAC1 and receptor activation (Knudsen et al., 2001).
A more recent study, that combined pharmacological and in
silico approaches, identiﬁed a network of interactions between
residues located in helices 2, 3, and 7 of theVPAC1 receptor, which
could be involved in the stabilization of the receptor in absence
of agonist and in early steps of receptor activation. It was pro-
posed that, in absence of ligand, interaction between R188, N229,
and Q380 ties helices 2, 3, and 7 together (Figure 3). Upon VIP
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FIGURE 2 | Snake-plot representation ofVPAC1 receptor. Amino acid
sequence of human VPAC1 receptor, the position of signal peptide,
glycosylated residues, and amino acids important for VIP binding, receptor
activation, and G protein coupling are also labeled.
binding, the interaction between R188 and N380 is broken and a
stronger interaction (salt bridge) is established between R188 and
the D3 side chain of VIP. TM2 and probably other helices undergo
conformational changes causing key sequences located in intracel-
lular loops to be exposed and to interact with the G proteins. In
the meantime, the interaction network involving N229 and Q380
maintains TM7 in a conformation necessary for proper activation
of G proteins. The three-dimensional model also suggested that
Q380 could function as a ﬂoating “ferry-boat”, switching between
R188 and N229 residues’ side-chains hence contributing to signal
transduction propagation and activation of Gproteins (Chugunov
et al., 2010).
When considering other site-directed mutagenesis studies, it is
likely that a complex and larger network of interaction between
TM helices must be considered for stabilization of VPAC1 inactive
and active conformations (Figure 2). Indeed, the mutation into
arginine of H178 located at the bottom of TM2 led to a consti-
tutively activated VPAC1 receptor (Gaudin et al., 1998). Similarly,
mutation of T343, located at junction of the third intracellular
loop and TM6 of VPAC1, into lysine, proline, or alanine also led to
a constitutively activated receptor (Gaudin et al., 1999). Another
study showed that Y146 and Y150, located in TM1 of VPAC1, do
not interact directly withVIP but stabilize the correct active recep-
tor conformation (Perret et al., 2002). It was also observed that
K195 and D196 located at junction of TM2 and the ﬁrst extra-
cellular loop were essential for VPAC1 activation but were not
directly involved in VIP recognition (Langer et al., 2003). How all
these residues cooperate to propagate signal transduction afterVIP
binding remains to be elucidated and would require a model or a
structure of the activated receptor in complex with VIP. Particu-
larly the two N-terminal residues of VIP, H1 and S2, are likely to
affect, directly or indirectly, the interaction network involved in
receptor activation. In this line, a very recent study suggested that
K143, T144, and T147, located in TM1 of VPAC1 could interact with
H1 residue of VIP and play an important role in receptor activa-
tion (Ceraudo et al., 2012). Mutagenesis studies of VPAC2 are less
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FIGURE 3 |Three-dimensional model of the transmembrane domains of theVPAC1 receptor. Lateral (A) and top (B) view of a working model of human
VPAC1 receptor, TM, and residues identiﬁed as important for receptor stabilization are also labeled. Details regarding modeling procedure are described in
Chugunov et al. (2010).
exhaustive, however, some studies identiﬁed key residues involved
in receptor activation such as Y130 and Y134 located in TM1 (Per-
ret et al., 2002), K179 in TM2 (Vertongen et al., 2001), and N216 in
TM3 (Nachtergael et al., 2006), suggesting that VPAC1 andVPAC2
share a similar pattern of activation.Moreover, so far as all residues
that were identiﬁed as important for VPAC receptors activation
are highly conserved among GPCR-B family members, they may
therefore be involved in binding and activation mechanisms that
are common to the whole family.
MOLECULAR MECHANISMS INVOLVED IN VPAC/G PROTEIN
BINDING AND ACTIVATION
The α subunit of heterotrimeric G proteins has a central role in
interactionwith both the receptor and the effectors. Several studies
have shown that the C-terminal part of Gα subunit can directly
bind to the receptor and is involved in the coupling speciﬁcity
(Conklin et al., 1996). The current model of GPCR activation,
based on the study of family A GPCRs, proposes that when the
receptor switches to its active conformation, TM movements are
accompanied by intracellular loops switches leading to exposure
of the G protein binding pocket to cytosol and efﬁcient binding
to G protein. However, the diversity of sequences and loop sizes
as well as their ﬂexibility has made difﬁcult the identiﬁcation of a
speciﬁc set of residues deﬁning the coupling proﬁle.
For the VPAC1 receptor, Gα binding domains are mainly
located in the third intracellular loop (IC3) that contains subdo-
mains dedicated to the recognition of the different Gα subunits.
K322 located in proximal part of IC3 and E394 located at the junc-
tion of TM7 and the C-terminal tail are required for adenylate
cyclase activation but not for the coupling to the inositol trispho-
sphate/calcium pathway. The former being involved in direct
interaction with Gαs (G protein binding), as demonstrated by a
reduced sensitivity to GTP, while E394 triggering switch of Gαs
from inactive to active state (G protein activation; Couvineau
et al., 2003; Langer and Robberecht, 2005). Similarly, two other
sequences located in IC3 have been identiﬁed as important for
VIP-induced intracellular calcium increase but not cAMP produc-
tion. A small sequence, I328-R329-K330-S331, located in the central
part of IC3 is involved in efﬁcient binding of VPAC1 to Gαi/o and
Gαq (Langer et al., 2002), while R338 and L339, located at the dis-
tal part of IC3, mediate interaction of VPAC1 with Gαi/o (Langer
and Robberecht, 2005). Combining mutations in the proximal
and distal part of IC3 together with mutation of E394 gave rise
to a completely inactive VPAC1 receptor with respect adenylate
cyclase activation and intracellular calcium increase (Figure 2). In
VPAC2 receptors, L310 located in the proximal part of IC3 con-
tributes to Gαs activation and the proximal part of IC3 (R325 and
K328) is involved in both Gαs and Gα16 coupling. The combined
mutations of these three amino acids generates an inactive VPAC2
receptor with respect to [Ca2+]i increase and adenylate cyclase
activation (Langer et al., 2005).
Among the different members of the GPCR-B family, proximal
and distal domains of IC3 share conserved sequences that could
therefore represent common G protein binding motifs. In line
with this hypothesis, studies performed on other members of the
GPCR-B family identiﬁed the proximal domain of IC3 as essen-
tial for adenylate cyclase activation but the amino acids involved
may differ and additional conserved sequences located in other
intracellular regions of the receptor may also be necessary as seen
for glucagon (IC2; Cypess et al., 1999) and CGRP receptors (R151
located in IC1; Conner et al., 2006). The junctions of IC3 loop are
predicted tobeα-helical and it is assumed that the correct position-
ing of charged amino acids plays an important role in G protein
interaction. However, other data suggest that lipophilic and aro-
matic residues are also important for G protein interaction. It is
possible that IC3 loop junctions activate G protein directly or that
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they may serve as regions that control the loop conformation. As
mutations may change both direct interaction site and secondary
structure, it is difﬁcult to deﬁne more precisely the mechanisms
involved in IC3 loop/G protein interaction.
REGULATION OF VPAC RECEPTORS ACTIVITY
Besides coupling to the effectors, GPCR activation by agonists
also initiates the process of receptor desensitization, an adaptive
response contributing to rapidly fade the G protein signaling. This
process starts with phosphorylation of the receptors in intracel-
lular loops and carboxyl terminus by activity dependent kinases
(PKA and PKC) and/or by receptor activated dependent kinases
(GPCR kinases or GRK). GRK mediated phosphorylation of the
receptor promotes the high afﬁnity binding of β-arrestins to the
receptor, which both sterically interdicts further coupling of G
protein and may act as a signal transducer to activate for instance
MAPKs, AKT, and PI3 kinases. β-arrestins are also able to bind
proteins of the endocytic machinery including clathrin and adap-
tor protein AP2 and promotes receptor internalization (Shenoy
and Lefkowitz, 2011).
Like most GPCRs, VPAC1 and VPAC2 receptors are rapidly
phosphorylated after agonist exposure. Absence of inhibitory
effect of PKA and PKC inhibitors (Langer et al., 2005; Langlet
et al., 2005), use of dominant negative GRK and GRK over-
expression experiments (Shetzline et al., 2002; Huang et al., 2007),
suggest that GRK are the main kinases involved in VIP receptors
phosphorylation. VPAC1 receptor phosphorylation induces β-
arrestin translocation to cell membrane, however, over-expression
of β-arrestin in HEK 293 cells only causes a minor decrease in
cAMP, suggesting VPAC1 desensitization may occur through an
arrestin-independent mechanism (Shetzline et al., 2002). By using
site-directed mutagenesis studies, T429, S435, S447, S448, S449, S455
located in the C-terminus and S250 located in IC2 were identiﬁed
as potential candidates for VIP-induced VPAC1 receptor phos-
phorylation (Marie et al., 2003; Langlet et al., 2005; Figure 2).
Combining the mutations of these identiﬁed residues indicated
that the effect on phosphorylation was not additive and the
mutants tested maintained a phosphorylation level of about 30%
of that observed for the wild type receptor except when all the
Ser/Thr residues of the C-terminus were mutated (Langlet et al.,
2005). Although it was shown that VPAC1 forms a complex with
β-arrestin and this complex is transported into the cell during
endocytosis (Shetzline et al., 2002), direct correlation between the
VPAC1 phosphorylation level and internalization was not obvious
as in some mutated receptors a signiﬁcant reduction in phospho-
rylation has no or little effect on receptor internalization. For
instance, some VPAC1 truncated receptors were still internalized
while VIP-induced phosphorylation was undetectable thus sug-
gesting an arrestin-independentmechanismof internalization and
only mutation of all the Ser/Thr residues of the C-terminus and
S250 completely abolished VPAC1phosphorylation and internal-
ization (Langlet et al., 2005). VPAC1 and VPAC2 receptors are
both rapidly internalized following agonist exposure but differ
in their trafﬁcking pattern. After internalization, VPAC1 recep-
tors are not re-expressed at the cell surface within 2 h after
agonist washing (suggesting that VPAC1 binds with high afﬁn-
ity β-arrestin) while VPAC2 receptors are recycled back to the
cell surface (suggesting that VPAC2 binds β-arrestin with low
afﬁnity; Langlet et al., 2004, 2005). In VPAC2 receptors, it was
found that inactivating mutations that alter G protein coupling
reduced both receptor phosphorylation and internalization in a
manner that appeared directly linked to the alteration of the
Gαs and Gα16 coupling (Langer et al., 2005). As mutants stud-
ied do not affect phosphorylatable residues, this suggests that
impaired receptor phosphorylation and internalization directly
reﬂect the reduced ability of the mutants to adopt active receptor
conformation. However, another study showed that VIP stimu-
lated phosphorylation of N229Q VPAC1 and N216Q VPAC2 (two
mutants characterized by a decrease in potency and efﬁcacy of
VIP stimulated adenylate cyclase activity, by the absence of agonist
stimulated [Ca2+]i increase, by a preserved receptor recogni-
tion of agonists and antagonist and by a preserved sensitivity to
GTP) was only slightly decreased, that receptor internalization
was comparable to that of the wild type receptors but unlike
wild type VPAC1 the N229Q mutant was rapidly re-expressed
at the cell surface upon VIP washing (Nachtergael et al., 2006).
As N229and N216 residues are located in the middle of TM3,
it seems unlikely that they could be in direct interaction with
β-arrestin but probably contribute to receptor conformation nec-
essary for high afﬁnity binding with β-arrestin. This later study
thus suggests that receptor conformation necessary for activa-
tion and regulatory mechanisms could be different (Figure 4).
As mentioned before, β-arrestins are also able to act as a signal
transducer and activate G protein-independent signaling path-
ways but to date such a mechanism has not been described for the
VIP receptors.
VPAC RECEPTORS OLIGOMERIZATION
It is now well accepted that, like for single transmembrane recep-
tors, GPCRs are also able to form oligomeric complexes either
with themselves (homo-oligomerization) or with other receptors
(hetero-oligomerization) that may affect the properties of the
receptor. When considering the large repertoire of GPCRs, and
thus the multitude of potential oligomers that can be formed,
a challenging task consists in identifying the speciﬁcity and the
physiological relevance of the partners, and the functional con-
sequences of these associations. By far, the GPCR-A/rhodopsin
family has been the most extensively studied, and data collected
indicate that the consequences of oligomerizationmay be detected
at the level of both physiological and pharmacological ligand
recognition, in signaling properties as well as at desensitization
and internalization levels. Besides pharmacological and functional
regulation, it was also demonstrated that GPCR oligomerization
plays a role in receptor maturation and in expression at the cell
surface (Milligan, 2009; Maurice et al., 2011).
Regarding VPAC receptors, two studies performed on the
prostate cancer cell line LNCaP (Juarranz et al., 2001) and
adipocytes (Akesson et al., 2005) demonstrated that those cells
expressed both VPAC1 and VPAC2 receptors but differed in their
pharmacological response with respect to the selective VPAC1 and
VPAC2 agonists. LNCaP cells displayed a VPAC1-like phenotype
(the VPAC2 selective agonist being inactive) while adipocytes dis-
played aVPAC2-like phenotype (theVPAC1 selective agonist being
inactive). One possible explanation of these results might be the
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FIGURE 4 | Mechanisms involved in regulation ofVPAC1 activity.
Upon VIP binding wt VPAC1 (A) is rapidly phosphorylated through a
GRK-dependent mechanism and desensitized, phosphorylation promotes
high afﬁnity binding of β-arrestin to VPAC1 and internalization into
endosome through an arrestin- and dynamin-dependent mechanism. After
internalization VPAC1 is not re-expressed at the cell surface. In some
truncated VPAC1 receptors (B), VIP fails to induce GRK-mediated receptor
phosphorylation but the receptor is still able to internalize through an
arrestin-independent mechanism and is re-expressed at the cell surface.
Some VPAC1 receptor mutants (C), with decrease in potency and efﬁcacy
of VIP-stimulated adenylate cyclase activity, preserved receptor recognition
of agonists and antagonist and a preserved sensitivity to GTP, are still
phosphorylated and internalized and recycle back to cell surface.
formation of inactive receptors dimers neutralizing the receptor
expressed at the lowest concentration and letting only one recep-
tor active. First evidence that VPAC receptors form oligomers
came from a study of Harikumar et al. (2006) who demonstrated
by using biophysical methods that VPAC1 and VPAC2 receptors
formed constitutive homo- and hetero-oligomers but also het-
erodimers with secretin receptors that remained trapped into
the cells (Harikumar et al., 2006). In an attempt to evaluate
the functional consequences of hetero-oligomerization of VPAC
receptors, another study investigated the effect of coexpressing
VPAC1 and VPAC2 receptors in Chinese hamster ovary (CHO)
cells on ligand binding, adenylate cyclase activation, receptor
internalization, and trafﬁcking. Three agonists were used, the
natural ligand VIP, and selective VPAC1[K15,R16,L27]VIP(1-7)/
GRF(8-27)] and VPAC2[Ro 25-1553] agonists. They found that
pharmacological properties of cells expressing both receptors were
not different from those obtained when mixing cells expressing
each receptor individually. Similarly, VIP receptors co-expression
did not modify receptor internalization and trafﬁcking pat-
terns following exposure to VIP or selective agonists (Langer
et al., 2006). Although this study did not point out any phar-
macological consequences of constitutive heterodimerization of
VPAC1–VPAC2 receptors, it suggests that the pharmacological
proﬁle of the selective VPAC1 and VPAC2 receptors ligands that
was established in cells expressing one receptor subtype is also
applicable to cells that could express both receptors endoge-
nously. Thus making possible the activation, antagonism, or
downregulation of one receptor subtype without affecting the
other. Additional experiments are now needed to demonstrate
that these oligomers do exist in more physiological conditions
and identify physiological consequences, if any, of VIP receptors
oligomerization.
Some GPCRs are also able to form hetero-oligomers with
receptor activity-modifying proteins (RAMPs), a family of sin-
gle transmembrane accessory proteins (RAMP1, 2, and 3). More
particularly, hetero-oligomerization of RAMPs with two GPCR-
B family members, the calcitonin receptor and the calcitonin
receptor-like receptor, generates multiple receptor phenotypes
with different speciﬁcities for endogenous ligands. It has ﬁrst
been shown that VPAC1 receptors, but not VPAC2 receptors,
were also able to interact with RAMP1, 2, and 3. VPAC1–RAMP
complexes did not display altered ligand speciﬁcity compared
with VPAC1 alone. However, speciﬁc interaction with RAMP2
led to a signiﬁcant enhancement of VIP- and PACAP-induced
inositol phosphate hydrolysis with unaltered cAMP production
(Christopoulos et al., 2003). A more recent study, however,
observed that VPAC2increases cell surface expression of all three
RAMPs. As seen for VPAC1, VPAC2, and RAMP co-expression
had no or little effect on agonist-stimulated cAMP production
but RAMP1 and RAMP2 signiﬁcantly enhanced basal coupling
to Gαi (Wootten et al., 2012). The RAMPs being largely dis-
tributed throughout the nervous system and peripheral tissues,
it would be interesting to investigate more deeply the properties of
VPAC–RAMPcomplexes such as for example selective agonists and
antagonists speciﬁcity, receptor signaling through other pathways,
receptor desensitization and internalization.
CONCLUSION AND PERSPECTIVES
Vasoactive intestinal peptide plays diverse and important role in
the CNS, PNS, gastrointestinal tract, and immune functions and
VPAC receptors constitute potential targets for the treatment of
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several diseases such as neurodegenerative disorder, schizophre-
nia, asthma, diabetes, gastrointestinal motility disorder, Crohn’s
disease, and rheumatoid arthritis. A key limiting factor in this
ﬁeld is that all the currently useful pharmacological tools are pep-
tides, and thus limit their use in human therapy. The ﬁrst small
molecule antagonists of VPAC1 (Harikrishnan et al., 2012) and
VPAC2 (Chu et al., 2010) have been described recently and emerge
from high throughput screening of compound collection. How-
ever, all are low afﬁnity, micro molar range, antagonists and need
further improvement to expect to obtain druggable modulators
of VPAC receptors activity. Better understand of structure, lig-
and binding site, and molecular pharmacology of VPAC receptors
constitute thus a key information for the rationale design of VPAC
receptors modulators and potential druggable compounds.
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